Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(146 productos)
- Bcr-Abl(102 productos)
- EGFR(572 productos)
- FAK(72 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(245 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(79 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(268 productos)
Mostrar 6 subcategorías más
Se han encontrado 1431 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Fórmula:C17H17N3O4Forma y color:SolidPeso molecular:327.33GZD856
CAS:<p>GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.</p>Fórmula:C29H27F3N6OPureza:98%Forma y color:SolidPeso molecular:532.56XST-14
CAS:<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Fórmula:C16H21NO4Pureza:99.84% - 99.84%Forma y color:SolidPeso molecular:291.34VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Fórmula:C26H20Cl2F3N5O3S2Forma y color:SolidPeso molecular:642.5NVP-AAD777
CAS:<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Fórmula:C22H14F6N4Pureza:98%Forma y color:SolidPeso molecular:448.36ALK5-IN-29
CAS:<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Fórmula:C24H25FN8Forma y color:SolidPeso molecular:444.51Adhesamine
CAS:<p>Adhesamine, a dumbbell molecule, enhances cell adhesion, growth, neuron differentiation, and survival via MAPK/FAK.</p>Fórmula:C24H32Cl4N8O2S2Forma y color:SolidPeso molecular:670.51JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SForma y color:SolidPeso molecular:393.46EGFR/HER2/TS-IN-2
CAS:<p>EGFR/HER2/TS-IN-2: Strong EGFR, HER2 & TS inhibitor; EGFR IC50=0.173μM, HER2 IC50=0.125μM, TS IC50=1.12μM; kills MDA-MB-231 cells (IC50=1.69μM).</p>Fórmula:C26H21N7OS2Forma y color:SolidPeso molecular:511.62BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Fórmula:C24H31N5O4SPureza:98%Forma y color:SolidPeso molecular:485.6VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Fórmula:C26H21ClF3N5O3S2Forma y color:SolidPeso molecular:608.05FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Fórmula:C21H23F3N6OForma y color:SolidPeso molecular:432.44Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Fórmula:C12H12N4O5Forma y color:SolidPeso molecular:292.25INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Forma y color:SolidPeso molecular:380.23PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Fórmula:C26H29Cl2N5O3Pureza:97.01%Forma y color:SolidPeso molecular:530.45MAX-40279 hydrochloride
CAS:<p>MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.</p>Fórmula:C22H24ClFN6OSForma y color:SolidPeso molecular:474.98E-4177
CAS:<p>E-4177 is an angiotensin II type 1 receptor (AT1R) antagonist and can be used to study cardiovascular diseases.</p>Fórmula:C24H21N3O2Pureza:98.67% - 99.57%Forma y color:SolidPeso molecular:383.44Con B-1
CAS:<p>ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .</p>Fórmula:C38H52ClN7O6SForma y color:SolidPeso molecular:770.38MG-262
CAS:<p>MG-262 is a reversible proteasome inhibitor with multiple biological activities [1] [2] [3].</p>Fórmula:C25H42BN3O6Forma y color:SolidPeso molecular:491.43PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SForma y color:SolidPeso molecular:1056.72BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Forma y color:SolidPeso molecular:460.761,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Forma y color:SolidPeso molecular:557.54BCR-ABL1-IN-1
CAS:<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Fórmula:C18H12F3N3O2Forma y color:SolidPeso molecular:359.3Cenisertib
CAS:<p>Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well</p>Fórmula:C24H30FN7OForma y color:SolidPeso molecular:451.54MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Forma y color:SolidPeso molecular:346.38EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Forma y color:SolidPeso molecular:451.56MAX-40279
CAS:<p>MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.</p>Fórmula:C22H23FN6OSForma y color:SolidPeso molecular:438.52EGFR/HER2/TS-IN-1
CAS:<p>EGFR/HER2/TS-IN-1 inhibits EGFR (0.203 μM), HER2 (0.088 μM), TS (0.168 μM), and induces apoptosis in MCF7 cells.</p>Fórmula:C24H15N5O4S2Forma y color:SolidPeso molecular:501.54LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Forma y color:SolidPeso molecular:401.46AFG210
CAS:AFG210 is a novel first-generation “type II” FLT3 inhibitor.Fórmula:C19H14F3N3O2Forma y color:SolidPeso molecular:373.33VEGFR-2-IN-23
CAS:<p>VEGFR-2-IN-23 (11b) is a potent VEGFR-2 inhibitor with an IC50 of 0.34 nM, exhibits antitumor effects, and causes G1 cell cycle arrest.</p>Fórmula:C22H15N5O2Forma y color:SolidPeso molecular:381.39BI1002494
CAS:<p>BI1002494 is an effective and selective Syk inhibitor.</p>Fórmula:C23H25N3O5Pureza:98%Forma y color:SolidPeso molecular:423.46CHMFL-ABL/KIT-155
CAS:<p>CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).</p>Fórmula:C33H38F3N5O3Pureza:98%Forma y color:SolidPeso molecular:609.68EGFR-IN-51
CAS:<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Fórmula:C21H15N3O2SForma y color:SolidPeso molecular:373.43Lck-IN-1
CAS:<p>Lck-IN-1 is a potent inhibitor of lymphocyte protein tyrosine kinase (Lck) [1].</p>Fórmula:C14H15N5Forma y color:SolidPeso molecular:253.3Glufanide disodium
CAS:<p>Glufanide disodium is an immunomodulator.</p>Fórmula:C16H17N3O5Na2Forma y color:SolidPeso molecular:377.3AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Fórmula:C15H12N4SForma y color:SolidPeso molecular:280.35AG1433
CAS:<p>AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.</p>Fórmula:C16H15ClN2O2Forma y color:SolidPeso molecular:302.76α7 nAchR-JAK2-STAT3 agonist 1
CAS:<p>α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM).</p>Fórmula:C25H30O6Forma y color:SolidPeso molecular:426.5Burixafor hydrobromide
CAS:<p>Burixafor hydrobromide is an oral CXCR4 blocker with anti-angiogenic properties, potentially treating choroid neovascularization.</p>Fórmula:C27H52BrN8O3PPureza:98%Forma y color:SolidPeso molecular:647.644EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Forma y color:SolidPeso molecular:224.34FIIN-4
CAS:<p>FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.</p>Fórmula:C35H38N8O4Pureza:>99.99%Forma y color:SolidPeso molecular:634.73BCR-ABL-IN-5
CAS:BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.Fórmula:C25H21Cl2N5O2Forma y color:SolidPeso molecular:494.37Luxeptinib
CAS:<p>Luxeptinib (CG-806) is an oral, non-covalent pan-FLT3/BTK inhibitor for acute myeloid leukemia.</p>Fórmula:C25H17F4N5O2Forma y color:SolidPeso molecular:495.43WY-135
CAS:<p>WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).</p>Fórmula:C28H34ClN9O3SPureza:98%Forma y color:SolidPeso molecular:612.15GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Fórmula:C21H18ClF2N7O3Forma y color:SolidPeso molecular:489.86FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Fórmula:C22H26ClN7O2Forma y color:SolidPeso molecular:455.94THS-044
CAS:<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Fórmula:C11H12F3N3O3Pureza:99.89%Forma y color:SolidPeso molecular:291.23CP-547632 hydrochloride
CAS:<p>CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.</p>Fórmula:C20H25BrClF2N5O3SForma y color:SolidPeso molecular:568.86PHA-680626
CAS:<p>PHA-680626 is a PLK inhibitor, effective on resistant leukemia cells, with IC50: Plk1 (0.53 μM), Plk2 (0.07 μM), Plk3 (1.61 μM).</p>Fórmula:C23H26N6O2SForma y color:SolidPeso molecular:450.56VEGFR-2-IN-27
CAS:<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Fórmula:C25H21FN4O4Forma y color:SolidPeso molecular:460.46WDR5-IN-4
CAS:<p>WIN site inhibitor 1 is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM), with anti-cancer activity.</p>Fórmula:C25H22Cl2FN5OPureza:98%Forma y color:SolidPeso molecular:498.38EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SForma y color:SolidPeso molecular:434.31Sitravatinib malate
CAS:<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Fórmula:C37H35F2N5O9SPureza:98%Forma y color:SolidPeso molecular:763.76BTK-IN-22
CAS:<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52BIIB-057
CAS:<p>BIIB-057 is a selective Syk inhibitor.</p>Fórmula:C19H23N9OPureza:98%Forma y color:SolidPeso molecular:393.45Ibrutinib-MPEA
CAS:<p>Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.</p>Fórmula:C32H39N9O2Forma y color:SolidPeso molecular:581.71Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64pan-HER-IN-2
CAS:<p>pan-HER-IN-2 (Compound C6) is an orally active, reversible, broad-spectrum HER inhibitor that acts on EGFR (IC50: 0.72 nM), HER4 (IC50: 2.0 nM), EGFRT790M (IC50</p>Fórmula:C19H15BrClN5OForma y color:SolidPeso molecular:444.71EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Fórmula:C28H30N4O3Forma y color:SolidPeso molecular:470.56PF-00337210
CAS:<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Fórmula:C26H27N3O5Forma y color:SolidPeso molecular:461.51VEGFR-2-IN-20
CAS:<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Fórmula:C20H20N4O3SForma y color:SolidPeso molecular:396.46Depatuxizumab mafodotin
CAS:<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Forma y color:LiquidPDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Fórmula:C26H39N9Forma y color:SolidPeso molecular:477.65ALK2-IN-5
CAS:<p>ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].</p>Fórmula:C24H32N8O2Forma y color:SolidPeso molecular:464.56OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Forma y color:SolidPeso molecular:542.55SB-633825
CAS:<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Fórmula:C28H25N3O3SPureza:98%Forma y color:SolidPeso molecular:483.58Syk-IN-1
CAS:<p>Syk-IN-11 is a selective Syk inhibitor.</p>Fórmula:C18H22N8OForma y color:SolidPeso molecular:366.42CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Fórmula:C28H26F3N7O2Forma y color:SolidPeso molecular:549.55LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Fórmula:C27H42N4O2Pureza:98%Forma y color:SolidPeso molecular:454.65EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Fórmula:C25H25ClFN5O4Forma y color:SolidPeso molecular:513.95TG 100572
CAS:<p>TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2</p>Fórmula:C26H26ClN5O2Pureza:98%Forma y color:SolidPeso molecular:475.97Ebselen oxide
CAS:<p>Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.</p>Fórmula:C13H9NO2SePureza:98%Forma y color:SolidPeso molecular:290.18PD 166326
CAS:<p>PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.</p>Fórmula:C21H16Cl2N4O2Forma y color:SolidPeso molecular:427.28SMU-B
CAS:<p>SMU-B is a well-tolerated c-Met/ALK dual inhibitor.</p>Fórmula:C26H25Cl2FN4O2Pureza:98%Forma y color:SolidPeso molecular:515.41T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Fórmula:C30H25ClFN5O4Forma y color:SolidPeso molecular:574BTK-IN-23
CAS:<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Fórmula:C27H28N6O2Forma y color:SolidPeso molecular:468.55JAK3/BTK-IN-5
CAS:<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Fórmula:C19H22ClN7O2Forma y color:SolidPeso molecular:415.88EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Fórmula:C19H12BrClO2Forma y color:SolidPeso molecular:387.65Ficonalkib
CAS:<p>Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.</p>Fórmula:C29H39N7O3SForma y color:SolidPeso molecular:565.73GW768505A free base
CAS:<p>GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.</p>Fórmula:C27H19F4N5O3Forma y color:SolidPeso molecular:537.47OD36
CAS:<p>OD36: Potent RIPK2 inhibitor, IC50=5.3 nM; hinders ALK2 signaling and osteogenesis, KD=37 nM; targets ALK2 ATP pocket.</p>Fórmula:C16H15ClN4O2Pureza:99.89%Forma y color:SolidPeso molecular:330.77GDC-0834 Racemate
CAS:<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Fórmula:C33H36N6O3SForma y color:SolidPeso molecular:596.74EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Fórmula:C23H20N4O5S2Forma y color:SolidPeso molecular:496.56NSC-689857
CAS:<p>NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.</p>Fórmula:C25H29NO4Pureza:98%Forma y color:SolidPeso molecular:407.5TX-1123
CAS:<p>TX-1123: PTK/COX inhibitor, Src/eEF2-K/PKA/EGFR-K/PKC targeted, IC50 of 1.16μM(COX2), 15.7μM(COX1), low mitochondrial toxicity.</p>Fórmula:C20H24O3Forma y color:SolidPeso molecular:312.4MAX-40279 hemiadipate
CAS:<p>MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)</p>Fórmula:C50H56F2N12O6S2Forma y color:SolidPeso molecular:1023.19(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Fórmula:C24H25ClFN5O3Forma y color:SolidPeso molecular:485.94AZM475271
CAS:<p>AZM475271 is a potent and selective inhibitor of Src kinase(IC50 : 5 nM)</p>Fórmula:C23H27ClN4O3Pureza:99.78%Forma y color:SolidPeso molecular:442.94R916562
CAS:<p>R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.</p>Fórmula:C26H30ClN9SPureza:98%Forma y color:SolidPeso molecular:536.09ULK1-IN-2
CAS:<p>ULK1-IN-2, a potent anticancer agent, inhibits ULK1, induces apoptosis, blocks autophagy, and shows high cytotoxicity with an IC50 of 1.94 μM in A549 cells.</p>Fórmula:C19H16BrFN4O6Pureza:99.25% - 99.25%Forma y color:SolidPeso molecular:495.26ENMD-1198
CAS:<p>ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.</p>Fórmula:C20H25NO2Pureza:98%Forma y color:SolidPeso molecular:311.42FAK-IN-8
CAS:<p>FAK-IN-8 (compound 5h), a FAK inhibitor with an IC50 of 5.32 μM, exhibits potent anti-proliferative activity, making it suitable for use in cancer research [1].</p>Fórmula:C15H9Cl2N3O2SForma y color:SolidPeso molecular:366.22PHM16
CAS:<p>PHM16 is an ATP competitive FAK and FGFR2 inhibitor.</p>Fórmula:C20H22N6O4Pureza:98%Forma y color:SolidPeso molecular:410.43BI-1622
CAS:<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Fórmula:C26H24N10O2Forma y color:SolidPeso molecular:508.53TC-S 7003
CAS:TC-S 7003 (Lck Inhibitor) is a Lck inhibitor with anti-inflammatory activity that inhibits T-cell proliferation and can be used to study arthritis.Fórmula:C31H30N8OPureza:99.74%Forma y color:SolidPeso molecular:530.62ProMMP-9 inhibitor-3c
CAS:<p>ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.</p>Fórmula:C18H20FN3O2SForma y color:SolidPeso molecular:361.43BPTQ
CAS:<p>BPTQ: DNA intercalator, halts cancer cell growth by blocking S/G2/M phases.</p>Fórmula:C17H16N4SPureza:98%Forma y color:SolidPeso molecular:308.4EGFR-IN-57
CAS:<p>EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.</p>Fórmula:C22H15N3O2SForma y color:SolidPeso molecular:385.44CPL304110
CAS:<p>CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.</p>Fórmula:C25H30N6O2Forma y color:SolidPeso molecular:446.54EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Forma y color:SolidPeso molecular:479.57VEGFR-2-IN-19
CAS:<p>VEGFR-2-IN-19 (15b) effectively inhibits VEGFR2, induces apoptosis, and increases oxidative stress, showing potential as an anticancer drug.</p>Fórmula:C21H19N3O2Forma y color:SolidPeso molecular:345.39EGFR-IN-52
CAS:<p>EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.</p>Fórmula:C19H18N4O3SForma y color:SolidPeso molecular:382.44JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Forma y color:SolidPeso molecular:434.43M1002
CAS:<p>M1002, a HIF-2 agonist, boosts HIF-2alpha/ARNT activation and alters HIF-281alpha PAS-B, working with PHD inhibitors.</p>Fórmula:C15H8F6N2O2SPureza:99.95%Forma y color:SolidPeso molecular:394.29ZK-261991
CAS:<p>ZK-261991 is an orally active inhibitor of VEGFR tyrosine kinase(IC50 of 5 nM, VEGFR2).</p>Fórmula:C24H25N7O2Pureza:98%Forma y color:SolidPeso molecular:443.5HSP90-IN-13
CAS:<p>HSP90-IN-13 (5k): potent HSP90 inhibitor, IC50 25.07 nM, targets EGFR/VEGFR-2/Topo-2, blocks MCF-7 G2/M cycle, induces apoptosis.</p>Fórmula:C26H21N5O3SForma y color:SolidPeso molecular:483.54Ilorasertib hydrochloride
CAS:<p>Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s:</p>Fórmula:C25H22ClFN6O2SPureza:98.45%Forma y color:SolidPeso molecular:525JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SForma y color:SolidPeso molecular:413.45UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Fórmula:C18H14ClN3O2Forma y color:SolidPeso molecular:339.78CAY10583
CAS:<p>CAY10583 is a selective BLT2 agonist that increases TGF-β1 and bFGF, promotes keratinocyte migration, accelerates wound healing in diabetic mice.</p>Fórmula:C25H25NO3Pureza:98%Forma y color:SolidPeso molecular:387.47EGFR-IN-56
CAS:<p>EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.</p>Fórmula:C23H22N4O3SForma y color:SolidPeso molecular:434.51NSC 33994
CAS:<p>NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.</p>Fórmula:C28H42N2O2Pureza:98%Forma y color:SolidPeso molecular:438.65JAK3/BTK-IN-6
CAS:<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Fórmula:C21H17BF3N5O3Forma y color:SolidPeso molecular:455.2EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68AFG206
CAS:AFG206 is the novel first-generation type II" FLT3 inhibitor."Fórmula:C20H19N3O2Forma y color:SolidPeso molecular:333.38TM-233
CAS:<p>TM-233 is an inhibitor of both JAK/STAT and proteasome activities that acts by inducing cell death in myeloma cells.</p>Fórmula:C25H20O4Pureza:98%Forma y color:SolidPeso molecular:384.42BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Fórmula:C27H22F3N5O2Forma y color:SolidPeso molecular:505.49VS 8
CAS:<p>VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.</p>Fórmula:C26H20F3N3O3Forma y color:SolidPeso molecular:479.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Fórmula:C39H41N9O3Forma y color:SolidPeso molecular:683.8BCR-ABL-IN-2
CAS:<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Fórmula:C24H25Cl2N5O3Pureza:98%Forma y color:SolidPeso molecular:502.39MAX-40279 hemifumarate
CAS:<p>MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.</p>Fórmula:C48H50F2N12O6S2Forma y color:SolidPeso molecular:993.12JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SForma y color:SolidPeso molecular:593.11EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Forma y color:SolidPeso molecular:609.76TG 100801 Hydrochloride
CAS:<p>TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.</p>Fórmula:C33H31Cl2N5O3Pureza:98%Forma y color:SolidPeso molecular:616.54EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51NSC114792
CAS:<p>NSC114792 is a selective JAK3 inhibitor.</p>Fórmula:C26H32N4O2SPureza:98%Forma y color:SolidPeso molecular:464.62Atopaxar Hydrobromide
CAS:<p>Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H39BrFN3O5Pureza:98%Forma y color:SolidPeso molecular:608.54EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4Sch 13835
CAS:<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Fórmula:C15H10ClNO4SPureza:98%Forma y color:SolidPeso molecular:335.76EL-102
CAS:<p>EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.</p>Fórmula:C19H16N2O3S2Pureza:99.34%Forma y color:SolidPeso molecular:384.47SUN13837
CAS:<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Fórmula:C21H29N5O2Forma y color:SolidPeso molecular:383.49HS-438
CAS:<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Fórmula:C17H17N3O3SForma y color:SolidPeso molecular:343.4TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SForma y color:SolidPeso molecular:383.42EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49Nuvenzepine
CAS:<p>Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.</p>Fórmula:C19H20N4O2Pureza:98%Forma y color:SolidPeso molecular:336.39pan-HER-IN-1
CAS:<p>Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.</p>Fórmula:C19H14BrN5OForma y color:SolidPeso molecular:408.25FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Fórmula:C26H36N8OForma y color:SolidPeso molecular:476.62(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Fórmula:C17H19N3O2Forma y color:SolidPeso molecular:297.35AAE871
CAS:<p>AAE871 is a type I FLT3 inhibitor.</p>Fórmula:C24H34N8O2SForma y color:SolidPeso molecular:498.64EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64VEGFR2 Kinase Inhibitor II
CAS:<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Fórmula:C17H15BrN2OForma y color:SolidPeso molecular:343.22JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:519.42Atopaxar
CAS:<p>Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H38FN3O5Pureza:97.07% - 98.07%Forma y color:SolidPeso molecular:527.63BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Fórmula:C29H23F3N6O3Forma y color:SolidPeso molecular:560.53GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Forma y color:SolidPeso molecular:596.74Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Forma y color:SolidPeso molecular:268.23EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67ALK-IN-21
CAS:<p>ALK-IN-21 (B10) inhibits ALK WT (IC50: 4.59nM), L1196M (2.07nM), G1202R (5.95nM); curbs Karpas299, H2228 cell growth; for ALCL research.</p>Fórmula:C35H45ClN6O6S4Forma y color:SolidPeso molecular:809.48FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Fórmula:C22H21N5O3Forma y color:SolidPeso molecular:403.43HZ-A-005
CAS:<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Fórmula:C25H23ClN6O2Forma y color:SolidPeso molecular:474.94JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Forma y color:SolidPeso molecular:522.55JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Forma y color:SolidPeso molecular:334.35BTK-IN-9
CAS:<p>BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.</p>Fórmula:C25H19N7O4Forma y color:SolidPeso molecular:481.46BMS-243117
CAS:<p>BMS-243117: Selective LCK inhibitor, IC50=1.1µM, inhibits T cell growth, promising for immunosuppression, arthritis, asthma treatment.</p>Fórmula:C20H21ClN4O2SForma y color:SolidPeso molecular:416.92MBM-55S
CAS:<p>MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.</p>Fórmula:C36H39FN6O10Pureza:99.37% - 99.89%Forma y color:SolidPeso molecular:734.73CGI560
CAS:<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Fórmula:C29H27N5OForma y color:SolidPeso molecular:461.56EGFR-IN-60
CAS:<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>Fórmula:C28H28Cl2N6OForma y color:SolidPeso molecular:535.47FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Forma y color:SolidPeso molecular:419.48Y 11
CAS:<p>focal adhesion kinase (FAK) inhibitor</p>Fórmula:C8H17BrN4OPureza:98%Forma y color:SolidPeso molecular:265.15Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEGFR-IN-46
CAS:<p>EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.</p>Fórmula:C27H32F3N3O3Forma y color:SolidPeso molecular:503.56ZT55
CAS:<p>ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.</p>Fórmula:C17H16N2O3Forma y color:SolidPeso molecular:296.32JTV-519 free base
CAS:<p>JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmic</p>Fórmula:C25H32N2O2SPureza:98%Forma y color:SolidPeso molecular:424.6VEGFR-2-IN-24
CAS:<p>VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.</p>Fórmula:C28H23N3O6SForma y color:SolidPeso molecular:529.56FGFR4-IN-11
CAS:<p>FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.</p>Fórmula:C29H29N5O5Forma y color:SolidPeso molecular:527.57c-Met-IN-14
CAS:<p>c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.</p>Fórmula:C34H38ClFN4O7SForma y color:SolidPeso molecular:701.2ARQ 069
CAS:<p>ARQ 069 inhibits FGFR2 phosphorylation concentration-dependently (IC50: 9.7 µM), without affecting β-actin. Preferentially binds inactive FGFR1/2.</p>Fórmula:C18H15N3Pureza:98%Forma y color:SolidPeso molecular:273.33EGFR-IN-26
CAS:<p>EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.</p>Fórmula:C29H34N6O3Forma y color:SolidPeso molecular:514.62TRK/ALK-IN-1
<p>TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.</p>Fórmula:C31H35ClF2N8O2SForma y color:SolidPeso molecular:657.18FGFR3-IN-1
CAS:<p>FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).</p>Fórmula:C28H39N9O3SForma y color:SolidPeso molecular:581.73VA5 TG2 inhibitor
CAS:<p>VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.</p>Fórmula:C31H34N4O8Pureza:98%Forma y color:SolidPeso molecular:590.62TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Forma y color:SolidPeso molecular:310.35RET-IN-19
CAS:<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Fórmula:C28H28N6O4SForma y color:SolidPeso molecular:544.62EGFR-IN-59
CAS:<p>EGFR-IN-59: EGFR inhibitor, IC50 = 190 nM, induces apoptosis, cytotoxic to A549 cells (IC50 = 8.62 μM) and WI38 cells (IC50 = 52.6 μM). Use: Various cancers.</p>Fórmula:C27H23N5O4SForma y color:SolidPeso molecular:513.57EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SForma y color:SolidPeso molecular:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Fórmula:C13H11N3O2Forma y color:SolidPeso molecular:241.25RIPK2-IN-1
CAS:<p>RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM).</p>Fórmula:C23H27N5O3SForma y color:SolidPeso molecular:453.56Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Fórmula:C9H9NO3Forma y color:SolidPeso molecular:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OForma y color:SolidPeso molecular:415.25ALK-IN-22
CAS:<p>ALK-IN-22 suppresses ALK and mutants (IC50: 2.3-3.7 nM), hinders phosphorylation, and induces apoptosis in tumor studies.</p>Fórmula:C24H24ClN7O2Forma y color:SolidPeso molecular:477.95JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Fórmula:C26H30ClN7O2Forma y color:SolidPeso molecular:508.02AG-370
CAS:<p>AG 370, an indole tyrphostin, functions as a powerful inhibitor of PDGF-induced mitogenesis, demonstrating an IC50 of 20 μM.</p>Fórmula:C15H9N5Forma y color:SolidPeso molecular:259.27EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Forma y color:SolidPeso molecular:526.42CpCDPK1/TgCDPK1-IN-1
CAS:<p>CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.</p>Fórmula:C18H17N5Pureza:99.61%Forma y color:SolidPeso molecular:303.36FGFR3-IN-2
CAS:<p>FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor that inhibits FGFR3 (IC50: 4.1 nM) and VEGFR2 (IC50: 570 nM).</p>Fórmula:C28H39N9O4SForma y color:SolidPeso molecular:597.73CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Forma y color:SolidPeso molecular:303.36IHMT-TRK-284
CAS:<p>IHMT-TRK-284: Oral type II TRK inhibitor; targets TRKA, TRKB, TRKC (IC50s: 10.5, 0.7, 2.6 nM); selective and anti-tumor effective.</p>Fórmula:C25H27N7OSForma y color:SolidPeso molecular:473.59PDGFR-IN-1
CAS:<p>PDGFR-IN-1 is a platelet-derived growth factor receptor (PDGFR) inhibitor, strongly inhibiting PDGFRα and PDGFRβ, useful for studying solid tumors.</p>Fórmula:C25H30N8OPureza:99.13% - 99.49%Forma y color:SolidPeso molecular:458.56PDE5-IN-3
CAS:<p>PDE5-IN-3: Inhibits PDE5 (1.57 nM), EGFR (5.827 μM), Wnt pathway (1286.96 ng/mL), induces apoptosis, and has antitumor effects.</p>Fórmula:C21H14BrN5O2Forma y color:SolidPeso molecular:448.27TYK2-IN-12
CAS:<p>TYK2-IN-12: selective oral TYK2 inhibitor (Ki: 0.51 nM), blocks IL-12-induced IFNγ; IC50: human 2.7 µM, mouse 7.0 µM, used for psoriasis research.</p>Fórmula:C24H20F2N4O2Forma y color:SolidPeso molecular:434.44OD36 hydrochloride
CAS:<p>OD36 hydrochloride (OD-36 hydrochloride) is a potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 hydrochloride is a macrocyclic inhibitor that binds efficiently</p>Fórmula:C16H16Cl2N4O2Pureza:99.85%Forma y color:SolidPeso molecular:367.23Esuberaprost Sodium
CAS:<p>Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.</p>Fórmula:C23H27FN4O2Forma y color:SolidPeso molecular:410.48MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45
